Hypoxic regulation of the noncoding genome and NEAT

Briefings in Functional Genomics

Volumn 15, Issue 3, 2016, Pages 174-185

  Choudhry, Hani ^a,b   Mole, David R ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cancer; HIF; Hypoxia; Noncoding RNA

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1; MICRORNA; NUCLEAR ENRICHED ABUNDANT TRANSCRIPT 1 PROTEIN; PIWI INTERACTING RNA; PROTEIN; SMALL NUCLEOLAR RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNTRANSLATED RNA; NEAT1 LONG NON-CODING RNA, HUMAN;

ARTICLE; GENE CONTROL; GENETIC TRANSCRIPTION; GENOME; HUMAN; HYPOXIA; LUNG ADENOCARCINOMA; METASTASIS; NONHUMAN; GENE EXPRESSION REGULATION; GENETICS; HUMAN GENOME; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; HYPOXIA; NEOPLASMS; RNA, LONG NONCODING;

EID: 84979073180     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elv050     Document Type: Article

References (140)

1. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
2. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-14.
3. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
4. Gu YZ, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-13.
5. Elvidge GP, Glenny L, Appelhoff RJ, et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006;281:15215-26.
6. Hu CJ, Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74.
7. Wang V, Davis DA, Haque M, et al. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res 2005;65:3299-306.
8. Raval RR, Lau KW, Tran MG, et al. Contrasting properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von hippellindau-associated renal cell carcinoma. Mol Cell Biol 2005;25:5675-86.
9. Ortiz-Barahona A, Villar D, Pescador N, et al. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 2010;38:2332-45.
10. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012;12:9-22.
11. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148:399-408.
12. Kaelin WG, Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
13. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
14. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000;157:411-21.
15. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.
16. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
17. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207-14.
18. Imamura T, Kikuchi H, Herraiz MT, et al. HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer 2009;124:763-71.
19. Bertout JA, Majmundar AJ, Gordan JD, et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci USA 2009;106:14391-6.
20. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95.
21. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
22. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
23. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
24. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41.
25. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
26. Tanimoto K, Makino Y, Pereira T, et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000;19:4298-309.
27. Kamura T, Sato S, Iwai K, et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000;97:10430-5.
28. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
29. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
30. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
31. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002;417:975-8.
32. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86.
33. Hewitson KS, McNeill LA, Riordan MV, et al. Hypoxiainducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;277:26351-5.
34. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002;16:1466-71.
35. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-61.
36. Freedman SJ, Sun ZY, Poy F, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002;99:5367-72.
37. Dames SA, Martinez-Yamout M, De Guzman RN, et al. Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci USA 2002;99:5271-6.
38. O'Rourke JF, Tian YM, Ratcliffe PJ, et al. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem 1999;274:2060-71.
39. Pugh CW, O'Rourke JF, Nagao M, et al. Activation of hypoxiainducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 1997;272:11205-14.
40. Stolze IP, Tian YM, Appelhoff RJ, et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]. J Biol Chem 2004;279:42719-25.
41. Khan MN, Bhattacharyya T, Andrikopoulos P, et al. Factor inhibiting HIF (FIH-1) promotes renal cancer cell survival by protecting cells from HIF-1alpha-mediated apoptosis. Br J Cancer 2011;104:1151-9.
42. Zhang N, Fu Z, Linke S, et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 2010;11:364-78.
43. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.
44. Choudhry H, Schodel J, Oikonomopoulos S, et al. Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2 EMBO Rep 2014;15:70-6.
45. Schodel J, Oikonomopoulos S, Ragoussis J, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIPseq. Blood 2010;117:e207-17.
46. Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009;284:16767-75.
47. Xia X, Kung AL. Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. Genome Biol 2009;10:R113.
48. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 2009;106:4260-5.
49. Tausendschon M, Rehli M, Dehne N, et al. Genome-wide identification of hypoxia-inducible factor-1 and -2 binding sites in hypoxic human macrophages alternatively activated by IL-10. Biochim Biophys Acta 2015;1849:10-22.
50. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature 2012;489:101-8.
51. Liu L, Simon MC. Regulation of transcription and translation by hypoxia. Cancer Biol Ther 2004;3:492-7.
52. Wu C, So J, Davis-Dusenbery BN, et al. Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2. Mol Cell Biol 2011;31:4760-74.
53. Camps C, Saini HK, Mole DR, et al. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer 2014;13:13-28.
54. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.
55. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
56. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5:522-31.
57. Guimbellot JS, Erickson SW, Mehta T, et al. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics 2009;2:15.
58. Hebert C, Norris K, Scheper MA, et al. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007;6:5.
59. Ho JJ, Metcalf JL, Yan MS, et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 2012;287:29003-20.
60. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116.
61. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007;27:1859-67.
62. Pulkkinen K, Malm T, Turunen M, et al. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008;582:2397-401.
63. Bruning U, Cerone L, Neufeld Z, et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 2011;31:4087-96.
64. Xu X, Jia R, Zhou Y, et al. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol 2011;38:1385-93.
65. Donker RB, Mouillet JF, Nelson DM, et al. The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. Mol Hum Reprod 2007;13:273-9.
66. Voellenkle C, Rooij J, Guffanti A, et al. Deep-sequencing of endothelial cells exposed to hypoxia reveals the complexity of known and novel microRNAs. RNA 2012;18:472-84.
67. Gee HE, Ivan C, Calin GA, et al. HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal 2014;21:1220-38.
68. McCormick R, Buffa FM, Ragoussis J, et al. The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol 2010;345:47-70.
69. Huang X, Zuo J. Emerging roles of miR-210 and other noncoding RNAs in the hypoxic response. Acta Biochim Biophys Sin (Shanghai) 2014;46:220-32.
70. Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008;7:255-64.
71. Zhang Z, Sun H, Dai H, et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009;8:2756-68.
72. Tsuchiya S, Fujiwara T, Sato F, et al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 2011;286:420-8.
73. He J, Wu J, Xu N, et al. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res 2013;41:498-508.
74. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008;283:15878-83.
75. Hu S, Huang M, Li Z, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010;122:S124-31.
76. McCormick RI, Blick C, Ragoussis J, et al. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013;108:1133-42.
77. Crosby ME, Kulshreshtha R, Ivan M, et al. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009;69:1221-9.
78. Kim HW, Mallick F, Durrani S, et al. Concomitant activation of miR-107/PDCD10 and hypoxamir-210/Casp8ap2 and their role in cytoprotection during ischemic preconditioning of stem cells. Antioxid Redox Signal 2012;17:1053-65.
79. Du R, Sun W, Xia L, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS One 2012;7:e30771.
80. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-74.
81. Moyano M, Stefani G. piRNA involvement in genome stability and human cancer. J Hematol Oncol 2015;8:38.
82. Mannoor K, Liao J, Jiang F. Small nucleolar RNAs in cancer. Biochim Biophys Acta 2012;1826:121-8.
83. Cheetham SW, Gruhl F, Mattick JS, et al. Long noncoding RNAs and the genetics of cancer. Br J Cancer 2013;108:2419-25.
84. Di Gesualdo F, Capaccioli S, Lulli M. A pathophysiological view of the long non-coding RNA world. Oncotarget 2014;5:10976-96.
85. Hajjari M, Salavaty A. HOTAIR: an oncogenic long noncoding RNA in different cancers. Cancer Biol Med 2015;12:1-9.
86. Shahryari A, Jazi MS, Samaei NM, et al. Long non-coding RNA SOX2OT: expression signature, splicing patterns, and emerging roles in pluripotency and tumorigenesis. Front Genet 2015;6:196.
87. Hu X, Feng Y, Zhang D, et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 2014;26:344-57.
88. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta 2013;1832:1613-23.
89. Kornfeld JW, Bruning JC. Regulation of metabolism by long, non-coding RNAs. Front Genet 2014;5:57.
90. Matouk IJ, Raveh E, Abu-lail R, et al. Oncofetal H19 RNA promotes tumor metastasis. Biochim Biophys Acta 2014;1843:1414-26.
91. Du Z, Fei T, Verhaak RG, et al. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol 2013;20:908-13.
92. Matouk IJ, Mezan S, Mizrahi A, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer. Biochim Biophys Acta 2010;1803:443-51.
93. Matouk IJ, DeGroot N, Mezan S, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007;2:e845.
94. Yang F, Zhang H, Mei Y, et al. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell 2014;53:88-100.
95. Wang Y, Liu X, Zhang H, et al. Hypoxia-inducible lncRNAAK058003 promotes gastric cancer metastasis by targeting gamma-synuclein. Neoplasia 2014;16:1094-106.
96. Xue M, Li X, Li Z, et al. Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol 2014;35:6901-12.
97. Ferdin J, Nishida N, Wu X, et al. HINCUTs in cancer: hypoxiainduced noncoding ultraconserved transcripts. Cell Death Differ 2013;20:1675-87.
98. Zhou C, Ye L, Jiang C, et al. Long noncoding RNA HOTAIR, a hypoxia-inducible factor-1alpha activated driver of malignancy, enhances hypoxic cancer cell proliferation, migration, and invasion in non-small cell lung cancer. Tumour Biol 2015;36:9179-88.
99. Gomez-Maldonado L, Tiana M, Roche O, et al. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene 2015;34:2609-20.
100. Yang F, Huo XS, Yuan SX, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 2013;49:1083-96.
101. Takahashi K, Yan IK, Haga H, et al. Modulation of hypoxiasignaling pathways by extracellular linc-RoR. J Cell Sci 2014;127:1585-94.
102. Wollenick K, Hu J, Kristiansen G, et al. Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Res 2012;40:1928-43.
103. Lelli A, Nolan KA, Santambrogio S, et al. induction of long noncoding rna MalaT1 in hypoxic mice. Hypoxia 2015;3:45-52.
104. Ip JY, Nakagawa S. Long non-coding RNAs in nuclear bodies. Dev Growth Differ 2012;54:44-54.
105. Nakagawa S, Ip JY, Shioi G, et al. Malat1 is not an essential component of nuclear speckles in mice. RNA 2012;18:1487-99.
106. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010;39:925-38.
107. Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in nonsmall cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011;6:1984-92.
108. Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014;114:1389-97.
109. Guru SC, Agarwal SK, Manickam P, et al. A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus. Genome Res 1997;7:725-35.
110. Naganuma T, Nakagawa S, Tanigawa A, et al. Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. Embo J 2012;31:4020-34.
111. Sunwoo H, Dinger ME, Wilusz JE, et al. MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. Genome Res 2009;19:347-59.
112. Choudhry H, Albukhari A, Morotti M, et al. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival. Oncogene 2015;34:4482-90.
113. Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell 2009;35:467-78.
114. Clemson CM, Hutchinson JN, Sara SA, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell 2009;33:717-26.
115. Sasaki YT, Ideue T, Sano M, et al. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci USA 2009;106:2525-30.
116. Hirose T, Virnicchi G, Tanigawa A, et al. NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies. Mol Biol Cell 2014;25:169-83.
117. Imamura K, Imamachi N, Akizuki G, et al. Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune stimuli. Mol Cell 2014;53:393-406
118. Prasanth KV, Prasanth SG, Xuan Z, et al. Regulating gene expression through RNA nuclear retention. Cell 2005;123:249-63.
119. Chen LL, DeCerbo JN, Carmichael GG. Alu element-mediated gene silencing. Embo J 2008;27:1694-705
120. Ben-Zvi M, Amariglio N, Paret G, et al. F11R expression upon hypoxia is regulated by RNA editing. PLoS One 2013;8:e77702.
121. Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci 2015;16:3251-66.
122. Fish JE, Matouk CC, Yeboah E, et al. Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem 2007;282:15652-66.
123. McCarty G, Loeb DM. Hypoxia-sensitive epigenetic regulation of an antisense-oriented lncRNA controls WT1 expression in myeloid leukemia cells. PLoS One 2015;10:e0119837.
124. Chen WM, Huang MD, Kong R, et al. Antisense long noncoding RNA HIF1A-AS2 is upregulated in gastric cancer and associated with poor Prognosis. Dig Dis Sci 2015;60: 1655-62.
125. Bertozzi D, Iurlaro R, Sordet O, et al. Characterization of novel antisense HIF-1alpha transcripts in human cancers. Cell Cycle 2011;10:3189-97.
126. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999;91:143-51.
127. Wang Y, Yao J, Meng H, et al. A novel long non-coding RNA, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. Mol Med Rep 2015;11:2534-40.
128. Sun YW, Chen YF, Li J, et al. A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br J Cancer 2014;111:2131-41.
129. Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 2008;68:5540-5.
130. Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer 2013;133:867-78.
131. Rane S, He M, Sayed D, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009;104:879-86.
132. Song XW, Li Q, Lin L, et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 2010;225:437-43.
133. Cascio S, D'Andrea A, Ferla R, et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010;224:242-9.
134. Lei Z, Li B, Yang Z, et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009;4:e7629.
135. Cha ST, Chen PS, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010;70:2675-85.
136. Yamakuchi M, Lotterman CD, Bao C, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010;107:6334-9.
137. Madanecki P, Kapoor N, Bebok Z, et al. Regulation of angiogenesis by hypoxia: the role of microRNA. Cell Mol Biol Lett 2013;18:47-57.
138. Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010;70:1635-44.
139. Ghosh G, Subramanian IV, Adhikari N, et al. Hypoxiainduced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest 2010;120:4141-54.
140. Kelly TJ, Souza AL, Clish CB, et al. A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol 2011;31:2696-706.